<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00307047</url>
  </required_header>
  <id_info>
    <org_study_id>05-368</org_study_id>
    <nct_id>NCT00307047</nct_id>
  </id_info>
  <brief_title>SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System</brief_title>
  <official_title>SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the SPIRIT IV Clinical Trial is to continue to evaluate the safety and
      efficacy of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V®). The XIENCE V®
      arm will be compared to an active control, represented by the FDA-approved TAXUS® EXPRESS2™
      Paclitaxel-Eluting Coronary Stent System (TAXUS®), commercially available from Boston
      Scientific.

      TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System is manufactured by Boston
      Scientific.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The completion of the SPIRIT IV clinical trial at three years is justified by the consistent
      long-term clinical evidence supporting the safety and efficacy of the XIENCE V EECSS in
      complex, real-world patients across multiple geographies. As SPIRIT IV was designed as a
      continued access trial, completing the clinical follow-up at the three-year visit does not
      conflict with any FDA requirements. Abbott Vascular is committed to providing clinical
      outcomes through three years. The clinical evidence provided from across multiple
      geographies, in complex populations thus supports Abbott Vascular's proposal to complete the
      SPIRIT IV RCT at the three-year clinical follow-up.

      The SPIRIT IV Clinical Trial is a randomized, active-controlled, single-blinded, multicenter
      clinical trial in the US that will enroll approximately 3,690 subjects (2:1 randomization
      XIENCE V®: TAXUS®). The trial allows the treatment of up to three de novo native coronary
      artery lesions, maximum of two lesion per epicardial vessel, with reference vessel diameters
      (RVD) ≥ 2.5 mm to ≤ 4.25 mm and lesion lengths ≤ 28 mm. (NOTE: RVD ≥ 2.5 mm to ≤ 3.75 mm
      until 4.0 mm TAXUS® is commercially available). All subjects will be screened per the
      protocol inclusion and exclusion criteria and enrolled subjects will have clinical follow-up
      at 30, 180, and 270 days and 1, 2, and 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ischemia Driven Target Lesion Failure (TLF)</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Failure (TVF)</measure>
    <time_frame>30 days</time_frame>
    <description>Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Failure (TVF)</measure>
    <time_frame>180 days</time_frame>
    <description>Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Failure (TVF)</measure>
    <time_frame>270 days</time_frame>
    <description>Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Failure (TVF)</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Failure (TVF)</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Failure (TVF)</measure>
    <time_frame>3 years</time_frame>
    <description>Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Lesion Revascularization (TLR)</measure>
    <time_frame>30 days</time_frame>
    <description>Revascularization of a target lesion associated with any of the following:
positive functional ischemia study
ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Lesion Revascularization (TLR)</measure>
    <time_frame>180 days</time_frame>
    <description>Revascularization of a target lesion associated with any of the following:
positive functional ischemia study
ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Lesion Revascularization (TLR)</measure>
    <time_frame>270 days</time_frame>
    <description>Revascularization of a target lesion associated with any of the following:
positive functional ischemia study
ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Lesion Revascularization (TLR)</measure>
    <time_frame>1 year</time_frame>
    <description>Revascularization of a target lesion associated with any of the following:
positive functional ischemia study
ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Lesion Revascularization (TLR)</measure>
    <time_frame>2 years</time_frame>
    <description>Revascularization of a target lesion associated with any of the following:
positive functional ischemia study
ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Lesion Revascularization (TLR)</measure>
    <time_frame>3 years</time_frame>
    <description>Revascularization of a target lesion associated with any of the following:
positive functional ischemia study
ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Revascularization (TVR)</measure>
    <time_frame>30 days</time_frame>
    <description>Revascularization of a lesion within the target vessel associated with any of the following:
positive functional ischemia study
ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Revascularization (TVR)</measure>
    <time_frame>180 days</time_frame>
    <description>Revascularization of a lesion within the target vessel associated with any of the following:
positive functional ischemia study
ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Revascularization (TVR)</measure>
    <time_frame>270 days</time_frame>
    <description>Revascularization of a lesion within the target vessel associated with any of the following:
positive functional ischemia study
ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Revascularization (TVR)</measure>
    <time_frame>1 year</time_frame>
    <description>Revascularization of a lesion within the target vessel associated with any of the following:
positive functional ischemia study
ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Revascularization (TVR)</measure>
    <time_frame>2 years</time_frame>
    <description>Revascularization of a lesion within the target vessel associated with any of the following:
positive functional ischemia study
ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Vessel Revascularization (TVR)</measure>
    <time_frame>3 years</time_frame>
    <description>Revascularization of a lesion within the target vessel associated with any of the following:
positive functional ischemia study
ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>30 days</time_frame>
    <description>Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>180 days</time_frame>
    <description>Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>270 days</time_frame>
    <description>Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>1 years</time_frame>
    <description>Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>2 years</time_frame>
    <description>Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>3 years</time_frame>
    <description>Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Success (Clinical Device)</measure>
    <time_frame>Acute: At time of index procedure</time_frame>
    <description>Successful delivery and deployment of the first implanted study stent (in overlapping stent setting a successful delivery and deployment of the first and second study stents) at the intended target lesion and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable). Bailout subjects will be included as device success only if the above criteria for clinical device are met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Success (Clinical Procedure)</measure>
    <time_frame>Acute: At time of index procedure</time_frame>
    <description>Successful delivery and deployment of the study stent or stents at the intended target lesion and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable) and/or using any adjunctive device without the occurrence of major adverse cardiac event (MACE) during the hospital stay with a maximum of first seven days following the index procedure. In multiple lesion setting all lesions must meet clinical procedure success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Myocardial Infarction (MI)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All MI</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All MI</measure>
    <time_frame>270 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All MI</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All MI</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All MI</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>270 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)</measure>
    <time_frame>270 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition</measure>
    <time_frame>0-30 days</time_frame>
    <description>ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: &gt;24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: &gt;1 year post
* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.
† Including &quot;primary&quot; as well as &quot;secondary&quot; late ST; &quot;secondary&quot; late ST is after a target segment revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite + Probable Stent Thrombosis Rate Based on ARC Definition</measure>
    <time_frame>31-393 days</time_frame>
    <description>ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: &gt;24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: &gt;1 year post
* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.
† Including &quot;primary&quot; as well as &quot;secondary&quot; late ST; &quot;secondary&quot; late ST is after a target segment revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite + Probable Stent Thrombosis Rate Based on ARC Definition</measure>
    <time_frame>0 -393 days</time_frame>
    <description>ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: &gt;24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: &gt;1 year post
* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.
† Including &quot;primary&quot; as well as &quot;secondary&quot; late ST; &quot;secondary&quot; late ST is after a target segment revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite + Probable Stent Thrombosis Rate Based on ARC Definition</measure>
    <time_frame>0-758 days</time_frame>
    <description>ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: &gt;24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: &gt;1 year post
* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.
† Including &quot;primary&quot; as well as &quot;secondary&quot; late ST; &quot;secondary&quot; late ST is after a target segment revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite + Probable Stent Thrombosis Rate Based on ARC Definition</measure>
    <time_frame>0-1123 days</time_frame>
    <description>ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: &gt;24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: &gt;1 year post
* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.
† Including &quot;primary&quot; as well as &quot;secondary&quot; late ST; &quot;secondary&quot; late ST is after a target segment revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protocol Defined Stent Thrombosis Rate</measure>
    <time_frame>0-30 days</time_frame>
    <description>ST will be categorized as acute (≤ 1day), subacute (&gt;1 day to ≤ 30 days) and late (&gt;30 days) and will be defined as any of the following:
Clinical presentation of acute coronary syndrome with angiographic evidence of ST
In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protocol Defined Stent Thrombosis Rate</measure>
    <time_frame>31-393 days</time_frame>
    <description>ST will be categorized as acute (≤ 1day), subacute (&gt;1 day to ≤ 30 days) and late (&gt;30 days) and will be defined as any of the following:
Clinical presentation of acute coronary syndrome with angiographic evidence of ST
In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protocol Defined Stent Thrombosis Rate</measure>
    <time_frame>0-393 days</time_frame>
    <description>ST will be categorized as acute (≤ 1day), subacute (&gt;1 day to ≤ 30 days) and late (&gt;30 days) and will be defined as any of the following:
Clinical presentation of acute coronary syndrome with angiographic evidence of ST
In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protocol Defined Stent Thrombosis Rate</measure>
    <time_frame>0-758 days</time_frame>
    <description>ST will be categorized as acute (≤ 1day), subacute (&gt;1 day to ≤ 30 days) and late (&gt;30 days) and will be defined as any of the following:
Clinical presentation of acute coronary syndrome with angiographic evidence of ST
In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protocol Defined Stent Thrombosis Rate</measure>
    <time_frame>0-1123 days</time_frame>
    <description>ST will be categorized as acute (≤ 1day), subacute (&gt;1 day to ≤ 30 days) and late (&gt;30 days) and will be defined as any of the following:
Clinical presentation of acute coronary syndrome with angiographic evidence of ST
In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death or Target Vessel MI Rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death or Target Vessel MI Rate</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death or Target Vessel MI Rate</measure>
    <time_frame>270 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death or Target Vessel MI Rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death or Target Vessel MI Rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death or Target Vessel MI Rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Lesion Failure (TLF)</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Lesion Failure (TLF)</measure>
    <time_frame>180 days</time_frame>
    <description>Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Lesion Failure (TLF)</measure>
    <time_frame>270 days</time_frame>
    <description>Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Lesion Failure (TLF)</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Target Lesion Failure (TLF)</measure>
    <time_frame>3 years</time_frame>
    <description>Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3687</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>XIENCE V®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TAXUS™ EXPRESS2™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE V® Everolimus Eluting Coronary Stent</intervention_name>
    <description>Drug eluting stent implantation stent in the treatment of coronary artery disease.</description>
    <arm_group_label>XIENCE V®</arm_group_label>
    <other_name>XIENCE V® Everolimus Eluting Coronary Stent System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent</intervention_name>
    <description>Drug eluting stent implantation stent in the treatment of coronary artery disease.</description>
    <arm_group_label>TAXUS™ EXPRESS2™</arm_group_label>
    <other_name>TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:

          -  Subject must be at least 18 years of age

          -  Subject is able to verbally confirm understanding of risks, benefits and treatment
             alternatives of receiving XIENCE V® and he/she or his/her legally authorized
             representative provides written informed consent prior to any study related procedure

          -  Subject must have evidence of myocardial ischemia (e.g., stable or unstable angina,
             silent ischemia, positive functional study or a reversible change in the
             electrocardiogram (ECG) consistent with ischemia)

          -  Subject must be an acceptable candidate for coronary artery bypass graft (CABG)
             surgery

          -  Subject must agree to undergo all protocol-required follow-up procedures

          -  Subject must agree not to participate in any other clinical study for a period of one
             year following the index procedure

        Angiographic Inclusion Criteria:

          -  Target lesion(s) must be located in a native coronary artery with visually estimated
             diameter of ≥2.5 mm to ≤4.25 mm and treatment of up to a three de novo target lesions,
             maximum of two de novo target lesions per epicardical vessel. (NOTE: RVD ≥2.5 mm to
             ≤3.75 mm until 4.0 mm TAXUS® is commercially available)

          -  Target lesion(s) must measure ≤28 mm in length by visual estimation(≥3 mm of
             non-diseased tissue on either side of the target lesion should be covered by the study
             stent)

          -  If more than one target lesion will be treated, the RVD and lesion length of each must
             meet the above criteria

          -  If more than one target lesion will be treated, the RVD and lesion length of each must
             meet the above criteria

          -  The target lesion(s) must be in a major artery or branch with a visually estimated
             stenosis of ≥ 50% and &lt; 100% with a TIMI flow of ≥ 1

          -  Non-study, percutaneous intervention for lesions in a target vessel (including side
             branches) is allowed if done ≥ 9 months prior to the index procedure

          -  Non-study percutaneous intervention for lesions in a non-target vessel involving:

          -  Successful and uncomplicated (visually estimated diameter stenosis &lt; 50%, TIMI Grade 3
             flow, no ECG changes, prolonged chest pain, or angiographic complications) bare-metal
             stent, balloon dilatation, cutting balloon, atherectomy, thrombectomy, and laser
             treatments are allowed if done ≥ 24 hours prior to the index procedure or during
             (before randomization) the index procedure. For interventions done within 24 to 48
             hours prior to the index procedure, CK and CK-MB must be assessed to be &lt; 2 times the
             upper limit of normal at the time of the index procedure. NOTE: Procedures within the
             24 hour period preceding the index procedure are not permitted

          -  Unsuccessful or complicated bare-metal stent, balloon dilatation, cutting balloon,
             atherectomy, thrombectomy, and laser treatments are allowed if done ≥ 30 days prior to
             the index procedure

          -  Drug-eluting stent treatment is allowed if done ≥ 90 days prior to the index procedure

          -  Non-study, percutaneous interventions for lesion(s) in a target vessel (including side
             branches) or non-target vessel are allowed if done ≥ 9 months after the index
             procedure

        General Exclusion Criteria:

          -  Subject has had a known diagnosis of acute myocardial infarction (AMI) preceding the
             index procedure (CK-MB ≥ 2 times upper limit of normal) and CK and CK-MB have not
             returned within normal limits at the time of procedure

          -  The subject is currently experiencing clinical symptoms consistent with AMI

          -  Subject has current unstable arrhythmias

          -  Subject has a known left ventricular ejection fraction (LVEF) &lt; 30%

          -  Subject has received a heart transplant or any other organ transplant or is on a
             waiting list for any organ transplant

          -  Subject is receiving or scheduled to receive anticancer therapy for malignancy within
             30 days prior to or after the procedure

          -  Subject is receiving immunosuppression therapy, or has known serious immunosuppressive
             disease (e.g., human immunodeficiency virus), or has severe autoimmune disease that
             requires chronic immunosuppressive therapy (e.g., systemic lupus erythematosus, etc.)

          -  Subject is receiving or is scheduled to receive chronic anticoagulation therapy (e.g.,
             heparin, coumadin)

          -  Subject has a known hypersensitivity or contraindication to aspirin, both heparin and
             bivalirudin, both clopidogrel and ticlopidine, everolimus, cobalt, chromium, nickel,
             tungsten, acrylic and fluoro polymers or contrast sensitivity that cannot be
             adequately pre-medicated

          -  Elective surgery that will require discontinuing either aspirin or clopidogrel is
             planned within the first 9 months after the procedure

          -  Subject has a platelet count &lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm3, a WBC of &lt;
             3,000 cells/mm3, or documented or suspected liver disease (including laboratory
             evidence of hepatitis)

          -  Subject has known renal insufficiency (e.g., serum creatinine level of &gt; 2.5 mg/dL or
             subject on dialysis)

          -  Subject has a history of bleeding diathesis or coagulopathy or will refuse blood
             transfusions

          -  Subject has had a cerebrovascular accident (CVA) or transient ischemic neurological
             attack (TIA) within the past six months

          -  Subject has had a significant GI or urinary bleed within the past six months

          -  Subject has extensive peripheral vascular disease that precludes safe 6 French sheath
             insertion

          -  Subject has other medical illness (e.g., cancer or congestive heart failure) or known
             history of substance abuse (alcohol, cocaine, heroin etc.) that may cause
             non-compliance with the protocol, confound the data interpretation or is associated
             with a life expectancy of less than one year

          -  Subject is already participating in another clinical study that has not yet reached
             its primary endpoint

          -  Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year
             following index procedure. (Female subjects of child-bearing potential must have a
             negative pregnancy test done within 7 days prior to the index procedure and effective
             contraception must be used up to 1 year following the index procedure)

          -  Angiographic Exclusion Criteria

          -  The target lesion(s) meets any of the following criteria:

          -  Left main coronary artery location including left main ostial location (NOTE:
             RCA-aorto-ostial lesions are not excluded)

          -  Located within 2 mm of the origin of the LAD or LCX

          -  Located within an arterial or saphenous vein graft or distal to a diseased (vessel
             irregularity per angiogram and any visually estimated diameter stenosis &gt; 20%)
             arterial or saphenous vein graft

          -  Involves a bifurcation in which the side branch is ≥ 2 mm in diameter AND the ostium
             of the side branch is &gt; 50% stenosed by visual estimation

          -  Involves a side branch requiring pre-dilatation

          -  Total occlusion (TIMI flow 0) prior to wire crossing

          -  Excessive tortuosity proximal to or within the lesion

          -  Extreme angulation (≥ 90º) proximal to or within the lesion

          -  Heavy calcification

          -  Restenotic from previous intervention

          -  Subject has received brachytherapy in any epicardial vessel (including side branches)

          -  The target vessel contains thrombus

          -  Another clinically significant lesion in the target vessel is present that requires or
             has a high probability of requiring PCI during the index procedure

          -  Another lesion in a target or non-target vessel (including all side branches) is
             present that requires or has a high probability of requiring PCI within 9 months after
             the index procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregg W Stone</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Heart Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Fairfax</city>
        <state>California</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Cardiovascular Associates</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Memorial Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital - LA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy General Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Medical Center of Santa Rosa</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95404-1797</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical Center of Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poudre Valley Hospital</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Hospital</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504-8721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Memorial Hospital</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital and Health Centers</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Center of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Heart Center P.C.</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Baptist Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Memorial Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Adventist Hospital</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <zip>20912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Medical Center</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Regional Medical Center</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakwood Hospital and Medical Center</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borgess Medical Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ingham Regional Medical Center</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Michigan Hospital</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Patrick Hospital</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Heart Hospital</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millard Fillmore Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital-Cornell</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Pomona</city>
        <state>New York</state>
        <zip>10970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook Hospital and Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital Health Center</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Hospital - Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitt County Memorial Hospital</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Medical Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EMH Regional Medical Center</name>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <zip>44035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence St. Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sisters of Charity Providence Hospitals</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Vniversity Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plaza Medical Center of Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center - Milwaukee</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2006</study_first_submitted>
  <study_first_submitted_qc>March 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2006</study_first_posted>
  <results_first_submitted>August 30, 2010</results_first_submitted>
  <results_first_submitted_qc>October 5, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 21, 2010</results_first_posted>
  <last_update_submitted>October 8, 2012</last_update_submitted>
  <last_update_submitted_qc>October 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stents</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Total coronary occlusion</keyword>
  <keyword>coronary restenosis</keyword>
  <keyword>stent thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects enrolled into this trial were comprised of male and female subjects from the general interventional cardiology population. Recruitment may have, but was not limited to a hospital or an interventional cardiology clinic. The enrollment period was August 10, 2006 through July 30, 2008.</recruitment_details>
      <pre_assignment_details>Patients who met inclusion/exclusion criteria were offered participation in the study, and randomized until the total trial population was reached.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>XIENCE V®</title>
          <description>Patients recieving the XIENCE V® stent</description>
        </group>
        <group group_id="P2">
          <title>TAXUS™ EXPRESS 2™</title>
          <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2458"/>
                <participants group_id="P2" count="1229"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2389"/>
                <participants group_id="P2" count="1180"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to follow-up for other reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>All death, all MI, all Revascularization</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>XIENCE V®</title>
          <description>Patients recieving the XIENCE V® stent</description>
        </group>
        <group group_id="B2">
          <title>TAXUS™ EXPRESS 2™</title>
          <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2458"/>
            <count group_id="B2" value="1229"/>
            <count group_id="B3" value="3687"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1373"/>
                    <measurement group_id="B2" value="677"/>
                    <measurement group_id="B3" value="2050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1085"/>
                    <measurement group_id="B2" value="552"/>
                    <measurement group_id="B3" value="1637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.25" spread="10.52"/>
                    <measurement group_id="B2" value="63.34" spread="10.23"/>
                    <measurement group_id="B3" value="63.28" spread="10.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="793"/>
                    <measurement group_id="B2" value="396"/>
                    <measurement group_id="B3" value="1189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1665"/>
                    <measurement group_id="B2" value="833"/>
                    <measurement group_id="B3" value="2498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2458"/>
                    <measurement group_id="B2" value="1229"/>
                    <measurement group_id="B3" value="3687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Vessel Failure (TVF)</title>
        <description>Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Vessel Failure (TVF)</title>
          <description>Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2451"/>
                <count group_id="O2" value="1222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Vessel Failure (TVF)</title>
        <description>Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR</description>
        <time_frame>180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Vessel Failure (TVF)</title>
          <description>Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2435"/>
                <count group_id="O2" value="1208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Vessel Failure (TVF)</title>
        <description>Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR</description>
        <time_frame>270 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Vessel Failure (TVF)</title>
          <description>Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2419"/>
                <count group_id="O2" value="1201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                    <measurement group_id="O2" value="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Vessel Failure (TVF)</title>
        <description>Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR</description>
        <time_frame>1 year</time_frame>
        <population>ITT, @ 1 yr</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Vessel Failure (TVF)</title>
          <description>Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR</description>
          <population>ITT, @ 1 yr</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2416"/>
                <count group_id="O2" value="1195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Vessel Failure (TVF)</title>
        <description>Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR</description>
        <time_frame>2 years</time_frame>
        <population>ITT, @ 2 years</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Vessel Failure (TVF)</title>
          <description>Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR</description>
          <population>ITT, @ 2 years</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2388"/>
                <count group_id="O2" value="1190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6"/>
                    <measurement group_id="O2" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Vessel Failure (TVF)</title>
        <description>Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR</description>
        <time_frame>3 years</time_frame>
        <population>ITT, @ 3 years</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Vessel Failure (TVF)</title>
          <description>Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR</description>
          <population>ITT, @ 3 years</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2348"/>
                <count group_id="O2" value="1158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Lesion Revascularization (TLR)</title>
        <description>Revascularization of a target lesion associated with any of the following:
positive functional ischemia study
ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
        <time_frame>30 days</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Lesion Revascularization (TLR)</title>
          <description>Revascularization of a target lesion associated with any of the following:
positive functional ischemia study
ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
          <population>ITT population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2451"/>
                <count group_id="O2" value="1222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Lesion Revascularization (TLR)</title>
        <description>Revascularization of a target lesion associated with any of the following:
positive functional ischemia study
ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
        <time_frame>180 days</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Lesion Revascularization (TLR)</title>
          <description>Revascularization of a target lesion associated with any of the following:
positive functional ischemia study
ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
          <population>ITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2435"/>
                <count group_id="O2" value="1208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Lesion Revascularization (TLR)</title>
        <description>Revascularization of a target lesion associated with any of the following:
positive functional ischemia study
ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
        <time_frame>270 days</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Lesion Revascularization (TLR)</title>
          <description>Revascularization of a target lesion associated with any of the following:
positive functional ischemia study
ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
          <population>ITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2419"/>
                <count group_id="O2" value="1201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Lesion Revascularization (TLR)</title>
        <description>Revascularization of a target lesion associated with any of the following:
positive functional ischemia study
ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
        <time_frame>1 year</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Lesion Revascularization (TLR)</title>
          <description>Revascularization of a target lesion associated with any of the following:
positive functional ischemia study
ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
          <population>ITT population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2416"/>
                <count group_id="O2" value="1195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1.94" upper_limit="3.23"/>
                    <measurement group_id="O2" value="4.6" lower_limit="3.49" upper_limit="5.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Lesion Revascularization (TLR)</title>
        <description>Revascularization of a target lesion associated with any of the following:
positive functional ischemia study
ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
        <time_frame>2 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Lesion Revascularization (TLR)</title>
          <description>Revascularization of a target lesion associated with any of the following:
positive functional ischemia study
ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
          <population>ITT population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2388"/>
                <count group_id="O2" value="1190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Lesion Revascularization (TLR)</title>
        <description>Revascularization of a target lesion associated with any of the following:
positive functional ischemia study
ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
        <time_frame>3 years</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Lesion Revascularization (TLR)</title>
          <description>Revascularization of a target lesion associated with any of the following:
positive functional ischemia study
ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
          <population>ITT population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2348"/>
                <count group_id="O2" value="1158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Vessel Revascularization (TVR)</title>
        <description>Revascularization of a lesion within the target vessel associated with any of the following:
positive functional ischemia study
ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Vessel Revascularization (TVR)</title>
          <description>Revascularization of a lesion within the target vessel associated with any of the following:
positive functional ischemia study
ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2451"/>
                <count group_id="O2" value="1222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Vessel Revascularization (TVR)</title>
        <description>Revascularization of a lesion within the target vessel associated with any of the following:
positive functional ischemia study
ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
        <time_frame>180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Vessel Revascularization (TVR)</title>
          <description>Revascularization of a lesion within the target vessel associated with any of the following:
positive functional ischemia study
ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2435"/>
                <count group_id="O2" value="1208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Vessel Revascularization (TVR)</title>
        <description>Revascularization of a lesion within the target vessel associated with any of the following:
positive functional ischemia study
ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
        <time_frame>270 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Vessel Revascularization (TVR)</title>
          <description>Revascularization of a lesion within the target vessel associated with any of the following:
positive functional ischemia study
ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2419"/>
                <count group_id="O2" value="1201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Vessel Revascularization (TVR)</title>
        <description>Revascularization of a lesion within the target vessel associated with any of the following:
positive functional ischemia study
ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Vessel Revascularization (TVR)</title>
          <description>Revascularization of a lesion within the target vessel associated with any of the following:
positive functional ischemia study
ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2416"/>
                <count group_id="O2" value="1195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Vessel Revascularization (TVR)</title>
        <description>Revascularization of a lesion within the target vessel associated with any of the following:
positive functional ischemia study
ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Vessel Revascularization (TVR)</title>
          <description>Revascularization of a lesion within the target vessel associated with any of the following:
positive functional ischemia study
ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2388"/>
                <count group_id="O2" value="1190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Vessel Revascularization (TVR)</title>
        <description>Revascularization of a lesion within the target vessel associated with any of the following:
positive functional ischemia study
ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Vessel Revascularization (TVR)</title>
          <description>Revascularization of a lesion within the target vessel associated with any of the following:
positive functional ischemia study
ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)
angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2348"/>
                <count group_id="O2" value="1158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1"/>
                    <measurement group_id="O2" value="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Major Adverse Cardiac Events (MACE)</title>
        <description>Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Major Adverse Cardiac Events (MACE)</title>
          <description>Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2451"/>
                <count group_id="O2" value="1222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Major Adverse Cardiac Events (MACE)</title>
        <description>Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR</description>
        <time_frame>180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Major Adverse Cardiac Events (MACE)</title>
          <description>Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2435"/>
                <count group_id="O2" value="1208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Major Adverse Cardiac Events (MACE)</title>
        <description>Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR</description>
        <time_frame>270 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Major Adverse Cardiac Events (MACE)</title>
          <description>Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2419"/>
                <count group_id="O2" value="1201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Major Adverse Cardiac Events (MACE)</title>
        <description>Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR</description>
        <time_frame>1 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Major Adverse Cardiac Events (MACE)</title>
          <description>Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2416"/>
                <count group_id="O2" value="1195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Major Adverse Cardiac Events (MACE)</title>
        <description>Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Major Adverse Cardiac Events (MACE)</title>
          <description>Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2388"/>
                <count group_id="O2" value="1190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Major Adverse Cardiac Events (MACE)</title>
        <description>Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Major Adverse Cardiac Events (MACE)</title>
          <description>Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2348"/>
                <count group_id="O2" value="1158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8"/>
                    <measurement group_id="O2" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Success (Clinical Device)</title>
        <description>Successful delivery and deployment of the first implanted study stent (in overlapping stent setting a successful delivery and deployment of the first and second study stents) at the intended target lesion and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable). Bailout subjects will be included as device success only if the above criteria for clinical device are met.</description>
        <time_frame>Acute: At time of index procedure</time_frame>
        <population>clinical device success is computed per lesion</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Success (Clinical Device)</title>
          <description>Successful delivery and deployment of the first implanted study stent (in overlapping stent setting a successful delivery and deployment of the first and second study stents) at the intended target lesion and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable). Bailout subjects will be included as device success only if the above criteria for clinical device are met.</description>
          <population>clinical device success is computed per lesion</population>
          <units>Percent of success</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3058"/>
                <count group_id="O2" value="1551"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0"/>
                    <measurement group_id="O2" value="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Success (Clinical Procedure)</title>
        <description>Successful delivery and deployment of the study stent or stents at the intended target lesion and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable) and/or using any adjunctive device without the occurrence of major adverse cardiac event (MACE) during the hospital stay with a maximum of first seven days following the index procedure. In multiple lesion setting all lesions must meet clinical procedure success.</description>
        <time_frame>Acute: At time of index procedure</time_frame>
        <population>Clinical procedure success is computed per subject</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Success (Clinical Procedure)</title>
          <description>Successful delivery and deployment of the study stent or stents at the intended target lesion and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable) and/or using any adjunctive device without the occurrence of major adverse cardiac event (MACE) during the hospital stay with a maximum of first seven days following the index procedure. In multiple lesion setting all lesions must meet clinical procedure success.</description>
          <population>Clinical procedure success is computed per subject</population>
          <units>Percentage of success</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2434"/>
                <count group_id="O2" value="1216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6"/>
                    <measurement group_id="O2" value="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Myocardial Infarction (MI)</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>All Myocardial Infarction (MI)</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2451"/>
                <count group_id="O2" value="1222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All MI</title>
        <time_frame>180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>All MI</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2435"/>
                <count group_id="O2" value="1208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All MI</title>
        <time_frame>270 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>All MI</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2419"/>
                <count group_id="O2" value="1201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All MI</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>All MI</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2416"/>
                <count group_id="O2" value="1195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All MI</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>All MI</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2388"/>
                <count group_id="O2" value="1190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All MI</title>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>All MI</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2348"/>
                <count group_id="O2" value="1158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2451"/>
                <count group_id="O2" value="1222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality</title>
        <time_frame>180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2435"/>
                <count group_id="O2" value="1208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality</title>
        <time_frame>270 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2419"/>
                <count group_id="O2" value="1201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2416"/>
                <count group_id="O2" value="1195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2388"/>
                <count group_id="O2" value="1190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality</title>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2348"/>
                <count group_id="O2" value="1158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2451"/>
                <count group_id="O2" value="1222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)</title>
        <time_frame>180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2435"/>
                <count group_id="O2" value="1208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5"/>
                    <measurement group_id="O2" value="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ischemia Driven Target Lesion Failure (TLF)</title>
        <description>Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR).</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Lesion Failure (TLF)</title>
          <description>Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR).</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2416"/>
                <count group_id="O2" value="1195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)</title>
        <time_frame>270 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2419"/>
                <count group_id="O2" value="1201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2416"/>
                <count group_id="O2" value="1195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0"/>
                    <measurement group_id="O2" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2388"/>
                <count group_id="O2" value="1190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5"/>
                    <measurement group_id="O2" value="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)</title>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2348"/>
                <count group_id="O2" value="1158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4"/>
                    <measurement group_id="O2" value="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition</title>
        <description>ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: &gt;24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: &gt;1 year post
* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.
† Including “primary” as well as “secondary” late ST; “secondary” late ST is after a target segment revascularization.</description>
        <time_frame>0-30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition</title>
          <description>ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: &gt;24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: &gt;1 year post
* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.
† Including “primary” as well as “secondary” late ST; “secondary” late ST is after a target segment revascularization.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2451"/>
                <count group_id="O2" value="1221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16"/>
                    <measurement group_id="O2" value="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Definite + Probable Stent Thrombosis Rate Based on ARC Definition</title>
        <description>ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: &gt;24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: &gt;1 year post
* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.
† Including “primary” as well as “secondary” late ST; “secondary” late ST is after a target segment revascularization.</description>
        <time_frame>31-393 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Definite + Probable Stent Thrombosis Rate Based on ARC Definition</title>
          <description>ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: &gt;24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: &gt;1 year post
* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.
† Including “primary” as well as “secondary” late ST; “secondary” late ST is after a target segment revascularization.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2391"/>
                <count group_id="O2" value="1181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13"/>
                    <measurement group_id="O2" value="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Definite + Probable Stent Thrombosis Rate Based on ARC Definition</title>
        <description>ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: &gt;24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: &gt;1 year post
* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.
† Including “primary” as well as “secondary” late ST; “secondary” late ST is after a target segment revascularization.</description>
        <time_frame>0 -393 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Definite + Probable Stent Thrombosis Rate Based on ARC Definition</title>
          <description>ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: &gt;24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: &gt;1 year post
* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.
† Including “primary” as well as “secondary” late ST; “secondary” late ST is after a target segment revascularization.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2391"/>
                <count group_id="O2" value="1181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29"/>
                    <measurement group_id="O2" value="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Definite + Probable Stent Thrombosis Rate Based on ARC Definition</title>
        <description>ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: &gt;24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: &gt;1 year post
* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.
† Including &quot;primary&quot; as well as &quot;secondary&quot; late ST; &quot;secondary&quot; late ST is after a target segment revascularization.</description>
        <time_frame>0-758 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Definite + Probable Stent Thrombosis Rate Based on ARC Definition</title>
          <description>ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: &gt;24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: &gt;1 year post
* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.
† Including &quot;primary&quot; as well as &quot;secondary&quot; late ST; &quot;secondary&quot; late ST is after a target segment revascularization.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2313"/>
                <count group_id="O2" value="1135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48"/>
                    <measurement group_id="O2" value="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Definite + Probable Stent Thrombosis Rate Based on ARC Definition</title>
        <description>ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: &gt;24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: &gt;1 year post
* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.
† Including &quot;primary&quot; as well as &quot;secondary&quot; late ST; &quot;secondary&quot; late ST is after a target segment revascularization.</description>
        <time_frame>0-1123 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Definite + Probable Stent Thrombosis Rate Based on ARC Definition</title>
          <description>ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: &gt;24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: &gt;1 year post
* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.
† Including &quot;primary&quot; as well as &quot;secondary&quot; late ST; &quot;secondary&quot; late ST is after a target segment revascularization.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2263"/>
                <count group_id="O2" value="1098"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62"/>
                    <measurement group_id="O2" value="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Protocol Defined Stent Thrombosis Rate</title>
        <description>ST will be categorized as acute (≤ 1day), subacute (&gt;1 day to ≤ 30 days) and late (&gt;30 days) and will be defined as any of the following:
Clinical presentation of acute coronary syndrome with angiographic evidence of ST
In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis.</description>
        <time_frame>0-30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Protocol Defined Stent Thrombosis Rate</title>
          <description>ST will be categorized as acute (≤ 1day), subacute (&gt;1 day to ≤ 30 days) and late (&gt;30 days) and will be defined as any of the following:
Clinical presentation of acute coronary syndrome with angiographic evidence of ST
In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2451"/>
                <count group_id="O2" value="1221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12"/>
                    <measurement group_id="O2" value="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Protocol Defined Stent Thrombosis Rate</title>
        <description>ST will be categorized as acute (≤ 1day), subacute (&gt;1 day to ≤ 30 days) and late (&gt;30 days) and will be defined as any of the following:
Clinical presentation of acute coronary syndrome with angiographic evidence of ST
In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis.</description>
        <time_frame>31-393 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Protocol Defined Stent Thrombosis Rate</title>
          <description>ST will be categorized as acute (≤ 1day), subacute (&gt;1 day to ≤ 30 days) and late (&gt;30 days) and will be defined as any of the following:
Clinical presentation of acute coronary syndrome with angiographic evidence of ST
In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2389"/>
                <count group_id="O2" value="1181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04"/>
                    <measurement group_id="O2" value="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Protocol Defined Stent Thrombosis Rate</title>
        <description>ST will be categorized as acute (≤ 1day), subacute (&gt;1 day to ≤ 30 days) and late (&gt;30 days) and will be defined as any of the following:
Clinical presentation of acute coronary syndrome with angiographic evidence of ST
In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis.</description>
        <time_frame>0-393 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Protocol Defined Stent Thrombosis Rate</title>
          <description>ST will be categorized as acute (≤ 1day), subacute (&gt;1 day to ≤ 30 days) and late (&gt;30 days) and will be defined as any of the following:
Clinical presentation of acute coronary syndrome with angiographic evidence of ST
In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2389"/>
                <count group_id="O2" value="1181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17"/>
                    <measurement group_id="O2" value="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Protocol Defined Stent Thrombosis Rate</title>
        <description>ST will be categorized as acute (≤ 1day), subacute (&gt;1 day to ≤ 30 days) and late (&gt;30 days) and will be defined as any of the following:
Clinical presentation of acute coronary syndrome with angiographic evidence of ST
In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis.</description>
        <time_frame>0-758 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Protocol Defined Stent Thrombosis Rate</title>
          <description>ST will be categorized as acute (≤ 1day), subacute (&gt;1 day to ≤ 30 days) and late (&gt;30 days) and will be defined as any of the following:
Clinical presentation of acute coronary syndrome with angiographic evidence of ST
In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2313"/>
                <count group_id="O2" value="1137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52"/>
                    <measurement group_id="O2" value="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Protocol Defined Stent Thrombosis Rate</title>
        <description>ST will be categorized as acute (≤ 1day), subacute (&gt;1 day to ≤ 30 days) and late (&gt;30 days) and will be defined as any of the following:
Clinical presentation of acute coronary syndrome with angiographic evidence of ST
In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis.</description>
        <time_frame>0-1123 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Protocol Defined Stent Thrombosis Rate</title>
          <description>ST will be categorized as acute (≤ 1day), subacute (&gt;1 day to ≤ 30 days) and late (&gt;30 days) and will be defined as any of the following:
Clinical presentation of acute coronary syndrome with angiographic evidence of ST
In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2266"/>
                <count group_id="O2" value="1104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79"/>
                    <measurement group_id="O2" value="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death or Target Vessel MI Rate</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death or Target Vessel MI Rate</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2451"/>
                <count group_id="O2" value="1222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death or Target Vessel MI Rate</title>
        <time_frame>180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death or Target Vessel MI Rate</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2435"/>
                <count group_id="O2" value="1208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death or Target Vessel MI Rate</title>
        <time_frame>270 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death or Target Vessel MI Rate</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2419"/>
                <count group_id="O2" value="1201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death or Target Vessel MI Rate</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death or Target Vessel MI Rate</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2416"/>
                <count group_id="O2" value="1195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death or Target Vessel MI Rate</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death or Target Vessel MI Rate</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2388"/>
                <count group_id="O2" value="1190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death or Target Vessel MI Rate</title>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death or Target Vessel MI Rate</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2348"/>
                <count group_id="O2" value="1158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Lesion Failure (TLF)</title>
        <description>Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR).</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Lesion Failure (TLF)</title>
          <description>Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR).</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2451"/>
                <count group_id="O2" value="1222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Lesion Failure (TLF)</title>
        <description>Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR).</description>
        <time_frame>180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Lesion Failure (TLF)</title>
          <description>Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR).</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2435"/>
                <count group_id="O2" value="1208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Lesion Failure (TLF)</title>
        <description>Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR).</description>
        <time_frame>270 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Lesion Failure (TLF)</title>
          <description>Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR).</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2419"/>
                <count group_id="O2" value="1201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Lesion Failure (TLF)</title>
        <description>Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR).</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Lesion Failure (TLF)</title>
          <description>Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR).</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2388"/>
                <count group_id="O2" value="1190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Target Lesion Failure (TLF)</title>
        <description>Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR).</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE V®</title>
            <description>Patients recieving the XIENCE V® stent</description>
          </group>
          <group group_id="O2">
            <title>TAXUS™ EXPRESS 2™</title>
            <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Target Lesion Failure (TLF)</title>
          <description>Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR).</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2348"/>
                <count group_id="O2" value="1158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>XIENCE V®</title>
          <description>Patients recieving the XIENCE V® stent</description>
        </group>
        <group group_id="E2">
          <title>TAXUS™ EXPRESS 2™</title>
          <description>Patients receiving the TAXUS™ EXPRESS 2™ stent</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="913" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="468" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="2436"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy mediastinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="2436"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="406" subjects_affected="304" subjects_at_risk="2436"/>
                <counts group_id="E2" events="196" subjects_affected="153" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="70" subjects_affected="60" subjects_at_risk="2436"/>
                <counts group_id="E2" events="48" subjects_affected="43" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="2436"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="44" subjects_affected="30" subjects_at_risk="2436"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Cardiac perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="2436"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Coronary artery perforation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="62" subjects_affected="58" subjects_at_risk="2436"/>
                <counts group_id="E2" events="43" subjects_affected="42" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" events="49" subjects_affected="46" subjects_at_risk="2436"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Gaze palsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Abdominal hernia obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="2436"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Abdominal symptom</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2436"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Erosive duodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2436"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Gastrooesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Intestinal malrotation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Intestinal mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Oesophageal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Oesophageal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Salivary gland mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="2436"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="2436"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="54" subjects_affected="47" subjects_at_risk="2436"/>
                <counts group_id="E2" events="29" subjects_affected="24" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="82" subjects_affected="57" subjects_at_risk="2436"/>
                <counts group_id="E2" events="30" subjects_affected="28" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Radiation associated pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Biliary dilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="2436"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Ischaemic hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess fungal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Breast cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Enterococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Infected sebaceous cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="42" subjects_affected="37" subjects_at_risk="2436"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="2436"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Asbestosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Brachial plexus injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Central line infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Coronary artery reocclusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Fracture nonunion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>In-stent coronary artery restenosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Mechanical complication of implant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Reperfusion injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Scrotal hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Stent-graft endoleak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Arthroscopy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase mb increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Blood glucose flactuation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2436"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Cardiac stress test abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Cardiac ventriculogram abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Computerised tomogram</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Fibrin d dimer increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Mediastinoscopy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Renal function test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2436"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus poor control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Diabetic retinal oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Weight loss poor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankylosing spondylitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="2436"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="2436"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="2436"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2436"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Arachnoid cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Benign renal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Bone neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Brain cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the duodenum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Dementia alzheimer's type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="2436"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Head and neck cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="2436"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Malignant urinary tract neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Throat cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Cerebral ventricle dilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="2436"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia facial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Occipital neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Spondylitic myelopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="2436"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="2436"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Unresponsive to stimuli</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="2436"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Renal artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Renal dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="2436"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="2436"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Renal hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Renal vessel disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Urinary tract disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="2436"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="2436"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Increased upper airway secretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pharyngeal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pleural disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="2436"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2436"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2436"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Restrictive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Throat tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="2436"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Scar pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Arterial bypass operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Arterial stent insertion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Carotid artery stent insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Carotid endarterectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Chemotherapy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Colostomy closure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass graft</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Coronary revascularisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Fluid replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Gastric banding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Gastric bypass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator insertion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Lung lobectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Nephrectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Parathyroid gland operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Percutaneous coronary intervention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Physiotherapy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Renal artery stent placement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Rotator cuff repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Salivary gland operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Skin neoplasm excision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Spinal fusion surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Spinal laminectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Spinal operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Transfusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Ureteral stent insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="2436"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="57" subjects_affected="47" subjects_at_risk="2436"/>
                <counts group_id="E2" events="26" subjects_affected="20" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="2436"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="2436"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Labile hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="2436"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2436"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Renovascular hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2436"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Subclavian steal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Subdural hematoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2436"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Vascular occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="2436"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Vasospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2436"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="762" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="407" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="493" subjects_affected="398" subjects_at_risk="2436"/>
                <counts group_id="E2" events="236" subjects_affected="198" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" events="181" subjects_affected="177" subjects_at_risk="2436"/>
                <counts group_id="E2" events="102" subjects_affected="98" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="194" subjects_affected="193" subjects_at_risk="2436"/>
                <counts group_id="E2" events="139" subjects_affected="130" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="126" subjects_affected="121" subjects_at_risk="2436"/>
                <counts group_id="E2" events="67" subjects_affected="64" subjects_at_risk="1214"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators will not use Trial related data without written consent of sponsor for any purpose other than Trial completion or generation of publication material. Publication or presentation of results from a trial site are not allowed until publication and/or presentation of multi-center results. Sponsor must receive materials at least 60 days prior to the proposed date of the presentation or the initial submission of proposed publication in order to be reviewed by the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ellen Travis</name_or_title>
      <organization>Abbott Vascular</organization>
      <phone>408-845-1512</phone>
      <email>ellen.travis@av.abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

